The RNA Analysis Market is expected to register a CAGR of 13.6% over the forecast period.
The onset of the COVID-19 pandemic impacted the studied market significantly. The outbreak of the pandemic increased the demand for testing and diagnosis following the severity of the infection caused by the SARS-CoV-2 virus. The number of research increased to find the genetic makeup of the virus. So that scientists can discover an efficient vaccine for the disease. Thus, the demand for next-generation sequencing (NGS) and polymerase chain reaction (PCR) increased. This significantly impacted the market growth. Hence, the COVID-19 pandemic had a favorable impact on the market initially. Currently, as the pandemic has subsided, the market has lost some traction; however, it is expected to have stable growth during the forecast period of the study.
In addition, PCR and NGS are being used to provide clinical advice on anti-inflammatory medications and to better understand the molecular structure of the host and the response to develop successful therapies. As per an article published in MDPI in July 2021, reverse-transcription polymerase chain reaction (RT-PCR) is the most used diagnostic test for SARS-CoV-2, and its widespread use is attributed to its simplicity and relatively high sensitivity. Thus, during the crucial phases of the pandemic, the market witnessed significant growth. However, as the pandemic has subsided currently, the market has lost some traction, but it is expected to have stable growth during the forecast period.
The factors expected to drive the market growth include the high prevalence of cancer across the world, the increasing infectious diseases, technological advancements, and the increasing demand for diagnosis and testing in healthcare. The rising demand for personalized medicine in oncology treatment, rising demand for research and development expenditure in RNA analysis, and the buying of platforms for the testing of pharmaceutical and biotechnology companies are driving the growth of the RNA analysis market.
Personalized medicine has entered mainstream clinical practice and is transforming how many diseases are detected, classified, and treated. It has become a fundamental focus of research in the healthcare business. Oncology is one area where these gains are particularly noticeable, with several tailored medications, therapies, and diagnostic tests that have grown for ages, and this trend is projected to continue in the coming years. According to the global cancer observatory data updated in March 2021 statistics, the number of cancer is expected to reach 28,887,840 by the year 2040. The increasing burden of the disease is also contributing to the increasing demand for RNA analysis products for developing innovative precision medicines for cancer. Hence, expected to drive the growth of the market over the analysis period.
Additionally, market players nowadays are focused more on product developments and innovations. This is also bolstering the growth of the market. For instance, in April 2022, Lexogen, a transcriptomics, and Next-Generation Sequencing company, introduced the new CORALL RNA-Seq V2 whole transcriptome library prep kit. Whole-transcriptome analysis with RNA sequencing (RNA-Seq) is at the cutting edge of NGS capabilities and allows the determination of RNA molecules in a sample during sampling. Furthermore, the strategic initiatives taken by the market players also augment the growth of the market. For instance, in January 2021, Merck acquired AmpTec to strengthen Merck's capabilities to develop and manufacture mRNA for its customers for use in vaccines, treatments, and diagnostics applicable to COVID-19 and many other diseases. Such company activities are expected to contribute to the market growth over the analysis period.
However, high costs associated with the analysis platforms and high capital investment in research and development are predicted to restrain the growth of the market studied over the forecast period.
According to the February 2022 update by WHO, cancer is one of the main causes of mortality worldwide, and cancer-causing infections, such as human papillomavirus (HPV) and hepatitis, are responsible for approximately 30% of cancer cases in low- and lower-middle-income countries. As a result of the high burden of cancer and infectious diseases, there is a greater demand for diagnosis in medical specialties and diagnostic care centers, which is expected to drive segmental growth during the forecast period.
Furthermore, the launch of products by the market players has propelled the growth of the market segment. For instance, in March 2021, PCR Biosystems, the United Kingdom-based specialist in DNA and RNA analysis, launched a range of Iso Fast BST Polymerase reagents for rapid, robust, and sensitive RNA amplification. Thus, owing to such product approvals, the segment is anticipated to witness significant growth during the analysis period.
Cancer is one of the most diagnosed genetic diseases that can be inherited or arise from certain environmental exposures. According to the American Cancer Society 2022 update, prostate cancer was the leading cause of cancer in males, while in females, it was breast cancer. In addition, as per the source above, by age group, people of age 65 years and more accounted for 1,117,640 cases of cancer, which was the highest among all other age groups. RNA sequencing has been utilized in many aspects of cancer research and therapy and provided an effective approach to detecting different types of cancers and other rare diseases. Thus, with the high burden of cancer and other diseases, the demand for RNA analysis technologies is growing, and it is propelling the growth of the market.
Furthermore, the commercial sector's continued investment in transcriptomics-related R&D is allowing regional market players to produce tailored medicines. The market in the region is growing due to advancements in sequencing technology, increased acceptance of NGS technology, and an increase in the number of partnerships and collaborations. For instance, in March 2022, Quantabio launched the sparQ RNA seq HMR kit. It is an ultra-fast RNA next-generation sequencing (NGS) library preparation tool with integrated ribosomal RNA (rRNA) and globin mRNA depletion.
Additionally, in June 2022, Fluent BioSciences launched two breakthrough products for three ′ single-cell RNA analyses, namely PIPseq T2 and T20 v3.0 kits. These capture up to 2,000 and 20,000 single cells or nuclei per reaction, respectively. Thus, owing to the abovementioned factors, the market in the region is expected to show significant growth over the forecast period.
This product will be delivered within 2 business days.
The onset of the COVID-19 pandemic impacted the studied market significantly. The outbreak of the pandemic increased the demand for testing and diagnosis following the severity of the infection caused by the SARS-CoV-2 virus. The number of research increased to find the genetic makeup of the virus. So that scientists can discover an efficient vaccine for the disease. Thus, the demand for next-generation sequencing (NGS) and polymerase chain reaction (PCR) increased. This significantly impacted the market growth. Hence, the COVID-19 pandemic had a favorable impact on the market initially. Currently, as the pandemic has subsided, the market has lost some traction; however, it is expected to have stable growth during the forecast period of the study.
In addition, PCR and NGS are being used to provide clinical advice on anti-inflammatory medications and to better understand the molecular structure of the host and the response to develop successful therapies. As per an article published in MDPI in July 2021, reverse-transcription polymerase chain reaction (RT-PCR) is the most used diagnostic test for SARS-CoV-2, and its widespread use is attributed to its simplicity and relatively high sensitivity. Thus, during the crucial phases of the pandemic, the market witnessed significant growth. However, as the pandemic has subsided currently, the market has lost some traction, but it is expected to have stable growth during the forecast period.
The factors expected to drive the market growth include the high prevalence of cancer across the world, the increasing infectious diseases, technological advancements, and the increasing demand for diagnosis and testing in healthcare. The rising demand for personalized medicine in oncology treatment, rising demand for research and development expenditure in RNA analysis, and the buying of platforms for the testing of pharmaceutical and biotechnology companies are driving the growth of the RNA analysis market.
Personalized medicine has entered mainstream clinical practice and is transforming how many diseases are detected, classified, and treated. It has become a fundamental focus of research in the healthcare business. Oncology is one area where these gains are particularly noticeable, with several tailored medications, therapies, and diagnostic tests that have grown for ages, and this trend is projected to continue in the coming years. According to the global cancer observatory data updated in March 2021 statistics, the number of cancer is expected to reach 28,887,840 by the year 2040. The increasing burden of the disease is also contributing to the increasing demand for RNA analysis products for developing innovative precision medicines for cancer. Hence, expected to drive the growth of the market over the analysis period.
Additionally, market players nowadays are focused more on product developments and innovations. This is also bolstering the growth of the market. For instance, in April 2022, Lexogen, a transcriptomics, and Next-Generation Sequencing company, introduced the new CORALL RNA-Seq V2 whole transcriptome library prep kit. Whole-transcriptome analysis with RNA sequencing (RNA-Seq) is at the cutting edge of NGS capabilities and allows the determination of RNA molecules in a sample during sampling. Furthermore, the strategic initiatives taken by the market players also augment the growth of the market. For instance, in January 2021, Merck acquired AmpTec to strengthen Merck's capabilities to develop and manufacture mRNA for its customers for use in vaccines, treatments, and diagnostics applicable to COVID-19 and many other diseases. Such company activities are expected to contribute to the market growth over the analysis period.
However, high costs associated with the analysis platforms and high capital investment in research and development are predicted to restrain the growth of the market studied over the forecast period.
RNorth America Analysis Market Trends
Reagents/Consumables Segment is Expected to Hold a Significant Share
The reagents and consumables are ready-to-use products to simplify RNA analysis procedures and research. During the forecast period, the increased prevalence of infectious diseases and oncological occurrences are also expected to boost the segment's growth. In addition, the demand for high-quality reagents is growing, as is the usage of media and reagents in transcriptome investigations. The biotechnological industry's increased R&D efforts, government spending on life science research, and the growing research being done with integrated omics studies are all contributing to the growth of the reagents/consumables segment's growth.According to the February 2022 update by WHO, cancer is one of the main causes of mortality worldwide, and cancer-causing infections, such as human papillomavirus (HPV) and hepatitis, are responsible for approximately 30% of cancer cases in low- and lower-middle-income countries. As a result of the high burden of cancer and infectious diseases, there is a greater demand for diagnosis in medical specialties and diagnostic care centers, which is expected to drive segmental growth during the forecast period.
Furthermore, the launch of products by the market players has propelled the growth of the market segment. For instance, in March 2021, PCR Biosystems, the United Kingdom-based specialist in DNA and RNA analysis, launched a range of Iso Fast BST Polymerase reagents for rapid, robust, and sensitive RNA amplification. Thus, owing to such product approvals, the segment is anticipated to witness significant growth during the analysis period.
North America is Expected to Hold a Significant Share of the Market
North America is expected to hold a significant share of the RNA analysis market due to the increasing product approvals and increasing cancer cases and infectious diseases in this region. The market in the region is also boosted by rising demand for various assay technologies, quantification of multiplexed RNA, the increased need for genetic testing and personalized treatment, and an increase in genetic variation and genetic mutation occurrences.Cancer is one of the most diagnosed genetic diseases that can be inherited or arise from certain environmental exposures. According to the American Cancer Society 2022 update, prostate cancer was the leading cause of cancer in males, while in females, it was breast cancer. In addition, as per the source above, by age group, people of age 65 years and more accounted for 1,117,640 cases of cancer, which was the highest among all other age groups. RNA sequencing has been utilized in many aspects of cancer research and therapy and provided an effective approach to detecting different types of cancers and other rare diseases. Thus, with the high burden of cancer and other diseases, the demand for RNA analysis technologies is growing, and it is propelling the growth of the market.
Furthermore, the commercial sector's continued investment in transcriptomics-related R&D is allowing regional market players to produce tailored medicines. The market in the region is growing due to advancements in sequencing technology, increased acceptance of NGS technology, and an increase in the number of partnerships and collaborations. For instance, in March 2022, Quantabio launched the sparQ RNA seq HMR kit. It is an ultra-fast RNA next-generation sequencing (NGS) library preparation tool with integrated ribosomal RNA (rRNA) and globin mRNA depletion.
Additionally, in June 2022, Fluent BioSciences launched two breakthrough products for three ′ single-cell RNA analyses, namely PIPseq T2 and T20 v3.0 kits. These capture up to 2,000 and 20,000 single cells or nuclei per reaction, respectively. Thus, owing to the abovementioned factors, the market in the region is expected to show significant growth over the forecast period.
RNorth America Analysis Market Competitor Analysis
The RNA analysis market is fragmented and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd, Illumina, Inc., QIAGEN, Eurofins Scientific, Merck KGaA, Bio-Rad Laboratories, Inc., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Promega Corporation, GenXPro GmbH, and BioMérieux SA, LC Sciences, among others.Additional benefits of purchasing the report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value - USD million)
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Thermo Fisher Scientific
- F. Hoffmann-La Roche Ltd
- Illumina,Inc
- QIAGEN
- Eurofins Scientific
- Merck KGaA
- Bio-Rad Laboratories, Inc.
- Agilent Technologies, Inc
- Bio-Rad Laboratories, Inc.
- Promega Corporation
- GenXPro GmbH
- BioMérieux SA
- LC Sciences
Methodology
LOADING...
